Mechanisms of CYP1A regulation and lung injury by oxygen

CYP1A调节与氧肺损伤的机制

基本信息

  • 批准号:
    6997438
  • 负责人:
  • 金额:
    $ 5.75万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2005
  • 资助国家:
    美国
  • 起止时间:
    2005-08-02 至 2008-08-01
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Hyperoxia is used routinely in patients suffering from pulmonary insufficiency, as is encountered in preterm infants and in adults with acute respiratory disease syndrome. The molecular mechanisms of lung injury caused by hyperoxia are not known. The central hypothesis of the research proposed here is that hyperoxia induces CYP1A enzymes in vivo and in cell culture systems by mechanisms involving transcriptional activation of the corresponding promoters, and that the induced CYP1A enzymes play protective roles in hyperoxic lung injury by catalyzing the detoxication of ROS-generated molecules (e.g., F2 isoprostanes and isofurans), whose levels are elevated in hyperoxic lungs. We proposed 2 Specific Aims. 1. To test the hypothesis that mice lacking the gene for CYP1A1, 1A2, or both genes (CYP1A1/1A2 double knockouts) will be more susceptible to hyperoxic lung injury than similarly exposed wild type mice. 2. To characterize the molecular mechanisms of modulation of CYP1A1 gene by hyperoxia in cultured mouse liver and lung cells. The proposed studies should aid in the development of novel strategies in the prevention/treatment of lung disease in humans undergoing supplemental oxygen therapy.
描述(由申请方提供):高氧通常用于肺功能不全患者,如早产儿和急性呼吸道疾病综合征成人。高氧引起肺损伤的分子机制尚不清楚。本文提出的研究的中心假设是,高氧通过涉及相应启动子的转录激活的机制在体内和细胞培养系统中诱导CYP 1A酶,并且诱导的CYP 1A酶通过催化ROS产生的分子(例如,F2异前列烷和异呋喃),其水平在高氧肺中升高。我们提出了两个具体目标。1.为了检验缺乏CYP 1A 1、1A 2基因或两种基因(CYP 1A 1/1A 2双敲除)的小鼠比类似暴露的野生型小鼠更容易发生高氧肺损伤的假设。2.探讨高氧对小鼠肝、肺细胞CYP 1A 1基因表达的影响及其分子机制。拟议的研究应有助于开发新的策略,在预防/治疗肺部疾病的人接受补充氧气治疗。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

WEIWU JIANG其他文献

WEIWU JIANG的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('WEIWU JIANG', 18)}}的其他基金

Mechanisms of CYP1A regulation and lung injury by oxygen
CYP1A调节与氧肺损伤的机制
  • 批准号:
    7113609
  • 财政年份:
    2005
  • 资助金额:
    $ 5.75万
  • 项目类别:
Mechanisms of CYP1A regulation and lung injury by oxygen
CYP1A调节与氧肺损伤的机制
  • 批准号:
    7266210
  • 财政年份:
    2005
  • 资助金额:
    $ 5.75万
  • 项目类别:

相似海外基金

Establishment of a Mouse NK Cell Line for Analyzing Tumor Infiltration Processes and Developing a Preclinical Model for Cancer Immunotherapy.
建立小鼠 NK 细胞系,用于分析肿瘤浸润过程并开发癌症免疫治疗的临床前模型。
  • 批准号:
    23K06731
  • 财政年份:
    2023
  • 资助金额:
    $ 5.75万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Proof of usefulness of PDX derived cell line
PDX 衍生细胞系的有用性证明
  • 批准号:
    23K06616
  • 财政年份:
    2023
  • 资助金额:
    $ 5.75万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
A novel producer cell line for more efficient manufacturing of viral vector systems
用于更有效地制造病毒载体系统的新型生产细胞系
  • 批准号:
    10597799
  • 财政年份:
    2023
  • 资助金额:
    $ 5.75万
  • 项目类别:
Genestorian: a web application to document and trace genetic modifications in model organism and cell line collections.
Genestorian:一个网络应用程序,用于记录和追踪模型生物和细胞系集合中的遗传修饰。
  • 批准号:
    EP/Y024591/1
  • 财政年份:
    2023
  • 资助金额:
    $ 5.75万
  • 项目类别:
    Fellowship
AI-Aided Tool for Day Zero Selection of High Performing Cells for Biopharma Cell Line Development
用于生物制药细胞系开发的高性能细胞零日选择的人工智能辅助工具
  • 批准号:
    10672364
  • 财政年份:
    2022
  • 资助金额:
    $ 5.75万
  • 项目类别:
Developing a stable cell line expressing recombinant sclerostin
开发表达重组硬化素的稳定细胞系
  • 批准号:
    10385037
  • 财政年份:
    2022
  • 资助金额:
    $ 5.75万
  • 项目类别:
Development of Natural Killer (NK) Cell Line-Derived Extracellular Vesicles as a New Treatment for Cancer
开发自然杀伤 (NK) 细胞系衍生的细胞外囊泡作为癌症的新治疗方法
  • 批准号:
    10383462
  • 财政年份:
    2022
  • 资助金额:
    $ 5.75万
  • 项目类别:
A cell culture management platform to improve biomedical reproducibility by combining cell line tracking, low-cost genetic analysis, and riskassessment
细胞培养管理平台,通过结合细胞系追踪、低成本遗传分析和风险评估来提高生物医学重现性
  • 批准号:
    10483063
  • 财政年份:
    2022
  • 资助金额:
    $ 5.75万
  • 项目类别:
AI-Aided Tool for Day Zero Selection of High Performing Cells for Biopharma Cell Line Development
用于生物制药细胞系开发的高性能细胞零日选择的人工智能辅助工具
  • 批准号:
    10546865
  • 财政年份:
    2022
  • 资助金额:
    $ 5.75万
  • 项目类别:
Modulating expression of candidate genes to improve lentiviral vector production in stable cell line
调节候选基因的表达以提高稳定细胞系中慢病毒载体的产量
  • 批准号:
    2752732
  • 财政年份:
    2022
  • 资助金额:
    $ 5.75万
  • 项目类别:
    Studentship
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了